ImmunityBio (IBRX) reported better-than-expected preliminary product revenues of approximately $44.2 million for Q1 2026, reflecting a 168% year-over-year growth. This figure surpassed the Zacks Consensus Estimate of $41 million. The revenue is primarily driven by product sales of Anktiva, an IL-15 receptor agonist approved for treating adults with BCG-unresponsive non-muscle invasive bladder cancer. Shares of IBRX rose by 7% following this announcement, bringing the year-to-date increase to 277.7%.
The company, based in La Jolla, California, ended the quarter with $380.9 million in cash and marketable securities, up from $242.8 million in Q4 2025. Anktiva is approved in 34 countries and has secured label expansion requests with the FDA, aiming to further increase its market reach in bladder cancer and other difficult-to-treat cancers.
